A BUDGET IMPACT (BI) ANALYSIS OF PEMETREXED IN COMBINATION WITH PEMBROLIZUMAB AND PLATINUM CHEMOTHERAPY FOR INITIAL TREATMENT OF PATIENTS WITH METASTATIC NON-SQUAMOUS (NSQ) NON-SMALL CELL LUNG CANCER (NSCLC) IN THE U.S.

Author(s)

Aggarwal H1, Muehlenbein CE1, Klein T2, Winfree KB1, Bly CA2, Zhu Y1, Perk S2, Smolen LJ2
1Eli Lilly and Company, Indianapolis, IN, USA, 2Medical Decision Modeling Inc., Indianapolis, IN, USA

OBJECTIVES

Given significantly improved survival shown in KEYNOTE-189 and KEYNOTE-21G trials with addition of pembrolizumab to pemetrexed and platinum chemotherapy (Pem+Pembro+Plat) compared to pemetrexed and platinum as initial treatment for patients with metastatic NSQ NSCLC, a BI analysis is warranted to estimate the impact on a payer’s budget from reimbursing Pem+Pembro+Plat.

METHODS

The BI analysis evaluated costs to a US commercial payer from addition of Pem+Pembro+Plat to a mix of existing treatment regimens. Applying published epidemiology data to a hypothetical one-million-member health plan, 206 patients per year with metastatic NSQ NSCLC, without EGFR or ALK aberrations, and eligible for initial therapy were estimated. Market share estimates were used to calculate number of patients receiving each regimen annually, with 40.5% of patients receiving Pem+Pembro+Plat when available. Acquisition, administration, and ancillary treatment-related costs were calculated for each regimen based on the average duration of treatment with each drug in the regimen from published data. Costs for grade 3+ adverse events were calculated from published studies. The BI analysis results were reported annually. One-way sensitivity analyses were performed on acquisition and adverse event costs.

RESULTS

Total cost without Pem+Pembro+Plat was $17,604,901 vs. $25,168,238 with Pem+Pembro+Plat, for a net increase of $7,563,337. Cost per member per month (PMPM) without Pem+Pembro+Plat was $1.467 vs. $2.097 with Pem+Pembro+Plat, for a net PMPM cost of $0.630. Cost per treated member per month (PTMPM) without Pem+Pembro+Plat was $7,105 vs. $10,158 with Pem+Pembro+Plat, for a net PTMPM cost of $3,052. One-way sensitivity analysis showed that changes in acquisition costs of pembrolizumab, bevacizumab, and pemetrexed had most impact on incremental total and per-member costs.

CONCLUSIONS

The increase in a US commercial payer’s annual budget from introduction of Pem+Pembro+Plat as a treatment option may be justifiable in light of improvement in survival with Pem+Pembro+Plat over traditional chemotherapy.

Conference/Value in Health Info

2019-05, ISPOR 2019, New Orleans, LA, USA

Value in Health, Volume 22, Issue S1 (2019 May)

Code

PCN98

Topic

Economic Evaluation, Health Service Delivery & Process of Care, Health Technology Assessment

Topic Subcategory

Budget Impact Analysis, Decision & Deliberative Processes, Formulary Development, Treatment Patterns and Guidelines

Disease

Oncology

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×